TOP HEADLINES

Featured Story

  • New technique generates stem cells at highly efficient rate

    Scientists at the New York University Langone Medical Center have developed a new technique that uses three familiar compounds, including vitamin C, to generate adult stem cells into pluripotent stem cells at a dramatically more efficient rate--more than 20-fold compared to the current method.

Drug development for tropical diseases gets $15.3M boost

Japan's Global Health Initiative Technology Fund is investing $15.3 million to speed the development of new drugs and vaccines for malaria, dengue and Chagas disease.

Naturally occurring antibiotic found in human bacterial colony

Scientists have discovered a natural antibiotic within a community of bacteria in the vagina, a finding that could point the way toward other human therapeutics.

Google's Calico acquires UT Southwestern compounds for neurodegenerative disorders

A new class of compounds discovered by investigators at the University of Texas Southwestern Medical Center that could treat a range of neurodegenerative disorders has caught the eye of Google's new biotechnology venture Calico.

Protein stops bone loss in arthritic mice

Researchers have pinpointed a small protein that may offer protection against bone loss associated with arthritis, a discovery that could lead to new treatments for the condition, which affects nearly one in 5 Americans.

Geneva Foundation gets $3M NIH grant for Ebola drug work

The Geneva Foundation, along with partner BioFactura, received a grant of more than $3 million from the U.S. National Institutes of Health to develop an antibody drug to combat the Sudan strain of the ebolavirus.

MORE NEWS

From Our Sister Sites

FiercePharma

Amgen is hoping to redeem its drug development rep by going to the FDA with an application for its new leukemia drug blinatumomab based on promising Phase II data, FierceBiotech reports.

FiercePharma

Generic drugmaker Par Pharmaceutical is throwing in the towel in its long-running fight with Santarus ($SNTS) over its heartburn med Zegerid, and $100 million along with it. It reported today that the payment will settle their back-and-forth patent suit.